好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Medication Reduction After Bilateral Globus Pallidus Internus Deep Brain Stimulation
Movement Disorders
P2 - Poster Session 2 (8:00 AM-9:00 AM)
5-032

To investigate the relationship between baseline patient characteristics and levodopa equivalent daily dose (LEDD) change following bilateral globus pallidus internus (GPi) deep brain stimulation (DBS) surgery in patients with Parkinson’s disease (PwP).

LEDD change after bilateral GPi DBS is not robustly characterized and existing data often include patients implanted before the advent of recent DBS technological advances such as directional leads.

Patient data, including LEDD, treatment side effects, age, sex, Montreal Cognitive Assessment (MoCA), Unified Parkinson’s Disease Rating Scale (UPDRS I, II, III-off, III-on), and cognitive diagnosis were retrospectively collected from a cohort of 45 PwP who underwent bilateral GPi DBS surgery between 2019 and 2023. Longitudinal LEDD data were retrospectively collected from three follow-up visits between 3 to 24 months postoperatively. Monthly rate of LEDD change was assessed for associations with baseline characteristics using random coefficient regression, Spearman correlation, and multiple regression analyses.

Postoperative monthly rate of LEDD change was -2.189 mg/month (95% CI [-8.711, 4.378]; p= 0.504), Baseline LEDD was negatively correlated with the predicted subject-specific rate of LEDD change (-0.33, 95% CI: [-0.58, -0.03]; p = 0.026), however this correlation was not significant on multiple regression analysis. The proportion of patients reporting treatment-related side effects decreased from 80% preoperatively to 31.1% between 12-14 months postoperatively, with no significant association between treatment side effects and the predicted rate of LEDD change.  No other baseline characteristic was significantly associated with the subject-specific predicted rate of LEDD change in either univariate analysis (p≥0.145) or multivariate analysis (p>0.275).

The change in LEDD from 3 to 24 months postoperatively in PwP undergoing bilateral GPI DBS was not significant. Patients with higher baseline LEDD may have a greater likelihood of reducing their LEDD postoperatively. No other baseline characteristic assessed had a significant predictive association with LEDD change.

Authors/Disclosures
Philip J. Lee, MD (Carilion Clinic Neurology)
PRESENTER
Dr. Lee has stock in Abbvie. Dr. Lee has stock in Annovis Bio Inc.. Dr. Lee has stock in Doximity. Dr. Lee has stock in Patterson Cos Inc. Dr. Lee has stock in Revance. Dr. Lee has stock in National Healthcare Corp. An immediate family member of Dr. Lee has stock in Johnson & Johnson Com. An immediate family member of Dr. Lee has stock in Candel Therapeutics Inc Com. An immediate family member of Dr. Lee has stock in Gilead Sciences Inc Com.
Xin Y. He, BS Mr. He has nothing to disclose.
James Patrie (University of Virginia) James Patrie has nothing to disclose.
Sajid Hameed Shaikh, MBBS, FCPS (Aga Khan University) Dr. Shaikh has nothing to disclose.
Alissa S. Higinbotham, MD (University of Virginia Medical Center) Dr. Kasunich has nothing to disclose.
William A. Dalrymple, MD (University of Virginia Health System) Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as a Consultant for REACH. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for M3. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Boxer Capital. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Capvision. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atheneum. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Cencora. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Lumanity. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Huntington Study Group. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Huntington Study Group. The institution of Dr. Dalrymple has received research support from Huntington's Disease Society of America.
Binit Shah, MD, FAAN (University of Virginia) Dr. Shah has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Expert Institute.
Renzo Figari-Jordan, MD, FAAN (University of Virginia) Dr. Figari-Jordan has nothing to disclose.